On January 2, 2025, Huda Y Zoghbi, a director at Regeneron Pharmaceuticals, was granted 166 shares of common stock at $0 per share. This transaction was reported as a direct acquisition, increasing Zoghbi's total beneficial ownership to 1,548 shares.The shares were acquired through a grant, award, or other acquisition program, as indicated by the transaction code 'A'. This type of transaction typically represents compensation or incentive awards for company executives and board members.The acquisition of these shares at no cost suggests they may be part of a restricted stock unit (RSU) grant or similar equity-based compensation plan. Such grants are common in the biotech and pharmaceutical industries to align the interests of key personnel with those of shareholders.

On January 2, 2025, Huda Y Zoghbi, a director at Regeneron Pharmaceuticals, was granted 166 shares of common stock at $0 per share. This transaction was reported as a direct acquisition, increasing Zoghbi's total beneficial ownership to 1,548 shares.The shares were acquired through a grant, award, or other acquisition program, as indicated by the transaction code 'A'. This type of transaction typically represents compensation or incentive awards for company executives and board members.The acquisition of these shares at no cost suggests they may be part of a restricted stock unit (RSU) grant or similar equity-based compensation plan. Such grants are common in the biotech and pharmaceutical industries to align the interests of key personnel with those of shareholders.